Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01263379 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
A Phase 1 study of Epidermolysis Bullosa and Epidermolysis Bullosa Dystrophica, sponsored by Abeona Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01263379 is a Phase 1 study of Epidermolysis Bullosa and Epidermolysis Bullosa Dystrophica that has completed, run by Abeona Therapeutics. The registered enrollment target is 12 participants, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01263379, a Phase 1 study of Epidermolysis Bullosa and Epidermolysis Bullosa Dystrophica, has completed, sponsored by Abeona Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will create a skin graft, which the investigators call "LEAES," using the patient's own skin cells that have been genetically engineered in the lab to express a missing protein called type VII collagen. The corrected cells will be transplanted back to the patient.
Conditions Studied
Interventions
- BIOLOGICAL LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Study Locations (1)
California
- Stanford University, School of Medicine, Dept of Dermatology - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-10-05 |
| Est. Completion | 2022-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01263379
The ClinicalTrials.gov registry entry for NCT01263379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The listed sponsor is Abeona Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which LZRSE-Col7A1 Engineered Autologous Epidermal Sheets is the first listed.
NCT01263379 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01263379 about?
NCT01263379 is a clinical study titled "Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa". This trial will create a skin graft, which the investigators call "LEAES," using the patient's own skin cells that have been genetically engineered in the lab to express a missing protein called type VII collagen. The corrected cells will be transplanted back to the patient.
What is the current status of trial NCT01263379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-10-05. Estimated completion is 2022-03-09.
What conditions does trial NCT01263379 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa, Epidermolysis Bullosa Dystrophica.
What interventions are being tested in trial NCT01263379?
The interventions under investigation include: LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (BIOLOGICAL).
Who is sponsoring clinical trial NCT01263379?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01263379 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
COMPLETED · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
-
Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
COMPLETED · Early Phase 1
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.